Physician

Carl G Chakmakjian, D.O.

According to 2025 Medicare claims, Carl Chakmakjian, D.O. (NPI: 1285675306) practices medical oncology in the Waco, TX market, with the plurality of this provider's patient population coming from Mc Lennan, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76712-2452. Chakmakjian is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Chakmakjian's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 604 traditional Medicare patients, billed 92,990 HCPCS/CPT codes, and received $1,958,929 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,584 prescription claims across 272 beneficiaries totaling $3,893,516 in drug costs, led by Revlimid (Lenalidomide). DME data shows 15 claims. Open Payments data shows 59 records totaling $42,007. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,212,169 to $3,893,516. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $2,394 to $335.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	494	114,751	$1,143,869
2016	583	151,433	$1,717,245
2017	669	161,293	$1,880,350
2018	661	148,248	$2,039,154
2019	642	198,046	$2,370,359
2020	654	131,150	$2,300,926
2021	611	102,903	$1,797,375
2022	566	143,870	$1,998,774
2023	596	121,589	$2,228,236
2024	604	92,990	$1,958,929

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	153	932	$1,212,169
2016	181	1,082	$1,649,066
2017	211	1,351	$1,632,123
2018	214	1,252	$1,224,184
2019	208	1,277	$1,352,258
2020	228	1,367	$1,956,617
2021	244	1,617	$3,468,077
2022	230	1,610	$3,758,876
2023	241	1,483	$2,864,591
2024	272	1,584	$3,893,516

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$13,793
2016	N/R	54	$8,572
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$2,076
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	11	$244
2023	N/R	40	$7,796
2024	N/R	15	$516

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	333	720	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	96	168	$62
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	235	498	$11
36415	Insertion of needle into vein for collection of blood sample	321	858	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	299	731	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	52	1,372	$837,846
Tibsovo	Ivosidenib	11	330	$364,826
Calquence	Acalabrutinib Maleate	24	713	$349,727
Verzenio	Abemaciclib	20	560	$297,786
Brukinsa	Zanubrutinib	28	795	$267,297

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$516

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	48	$24,851	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$17,156	GlaxoSmithKline, LLC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Carl G. Chakmakjian, D.O.?

Tedicare shows public-source Medicare data for Carl G. Chakmakjian, D.O. (NPI 1285675306), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Carl G. Chakmakjian, D.O. have ACO affiliation data?

Carl G. Chakmakjian, D.O. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Carl G. Chakmakjian, D.O.?

Carl G. Chakmakjian, D.O. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Carl G. Chakmakjian, D.O. have Open Payments data?

Carl G. Chakmakjian, D.O. has 59 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.